C
CU6
vs
S
S&P/ASX 300
Over the past 12 months, CU6 has underperformed S&P/ASX 300, delivering a return of -17% compared to the S&P/ASX 300's +4% growth.
Stocks Performance
CU6 vs S&P/ASX 300
Performance Gap
CU6 vs S&P/ASX 300
Performance By Year
CU6 vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.